PMID- 37636454
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240214
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 8
DP  - 2023 Aug
TI  - Time-resolved single-cell RNAseq profiling identifies a novel Fabp5(+) 
      subpopulation of inflammatory myeloid cells with delayed cytotoxic profile in 
      chronic spinal cord injury.
PG  - e18339
LID - 10.1016/j.heliyon.2023.e18339 [doi]
LID - e18339
AB  - Traumatic spinal cord injuries (SCI) are a group of highly debilitating 
      pathologies affecting thousands annually, and adversely affecting quality of 
      life. Currently, no fully restorative therapies exist, and SCI still results in 
      significant personal, societal and financial burdens. Inflammation plays a major 
      role in the evolution of SCI, with myeloid cells, including bone marrow derived 
      macrophages (BMDMs) and microglia (MG) being primary drivers of both early 
      secondary pathogenesis and delayed wound healing events. The precise role of 
      myeloid cell subsets is unclear as upon crossing the blood-spinal cord barrier, 
      infiltrating bone marrow derived macrophages (BMDMs) may take on the morphology 
      of resident microglia, and upregulate canonical microglia markers, thus making 
      the two populations difficult to distinguish. Here, we used time-resolved 
      scRNAseq and transgenic fate-mapping to chart the transcriptional profiles of 
      tissue-resident and -infiltrating myeloid cells in a mouse model of thoracic 
      contusion SCI. Our work identifies a novel subpopulation of foam cell-like 
      inflammatory myeloid cells with increased expression of Fatty Acid Binding 
      Protein 5 (Fabp5) and comprise both tissue-resident and -infiltrating cells. 
      Fabp5(+) inflammatory myeloid cells display a delayed cytotoxic profile that is 
      predominant at the lesion epicentre and extends into the chronic phase of SCI.
CI  - (c) 2023 The Authors.
FAU - Hamel, Regan
AU  - Hamel R
AD  - Department of Clinical Neurosciences and NIHR Biomedical Research Centre, 
      University of Cambridge, Cambridge, UK.
FAU - Peruzzotti-Jametti, Luca
AU  - Peruzzotti-Jametti L
AD  - Department of Clinical Neurosciences and NIHR Biomedical Research Centre, 
      University of Cambridge, Cambridge, UK.
FAU - Ridley, Katherine
AU  - Ridley K
AD  - Cambridge Stem Cell Institute, University of Cambridge, UK.
FAU - Testa, Veronica
AU  - Testa V
AD  - Department of Clinical Neurosciences and NIHR Biomedical Research Centre, 
      University of Cambridge, Cambridge, UK.
FAU - Yu, Bryan
AU  - Yu B
AD  - Department of Clinical Neurosciences and NIHR Biomedical Research Centre, 
      University of Cambridge, Cambridge, UK.
FAU - Rowitch, David
AU  - Rowitch D
AD  - Cambridge Stem Cell Institute, University of Cambridge, UK.
FAU - Marioni, John C
AU  - Marioni JC
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute 
      (EMBL-EBI), Wellcome Genome Campus, Hinxton, UK.
AD  - Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
FAU - Pluchino, Stefano
AU  - Pluchino S
AD  - Department of Clinical Neurosciences and NIHR Biomedical Research Centre, 
      University of Cambridge, Cambridge, UK.
LA  - eng
GR  - MC_PC_17230/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20230806
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10450865
OTO - NOTNLM
OT  - Fate-mapping myeloid cells
OT  - Fatty acid binding protein 5
OT  - Lipid metabolism
OT  - Microglia
OT  - Myeloid cells
OT  - Neurodegeneration
OT  - Neuroinflammation
OT  - Single cell RNA sequencing
OT  - Spinal cord injury
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/08/28 06:42
MHDA- 2023/08/28 06:43
PMCR- 2023/08/06
CRDT- 2023/08/28 04:36
PHST- 2022/11/01 00:00 [received]
PHST- 2023/07/09 00:00 [revised]
PHST- 2023/07/13 00:00 [accepted]
PHST- 2023/08/28 06:43 [medline]
PHST- 2023/08/28 06:42 [pubmed]
PHST- 2023/08/28 04:36 [entrez]
PHST- 2023/08/06 00:00 [pmc-release]
AID - S2405-8440(23)05547-0 [pii]
AID - e18339 [pii]
AID - 10.1016/j.heliyon.2023.e18339 [doi]
PST - epublish
SO  - Heliyon. 2023 Aug 6;9(8):e18339. doi: 10.1016/j.heliyon.2023.e18339. eCollection 
      2023 Aug.